Brady L Stein

List of Publications by Year
in descending order

58 papers	1,058 citations	471509 17 h-index	414414 32 g-index
58 all docs	58 docs citations	58 times ranked	1880 citing authors

#	Article	IF	Citations
1	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis. JAMA Oncology, 2018, 4, 652.	7.1	261
2	Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica, 2011, 96, 1462-1469.	3.5	83
3	Central Role of ULK1 in Type I Interferon Signaling. Cell Reports, 2015, 11, 605-617.	6.4	66
4	Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leukemia and Lymphoma, 2013, 54, 1989-1995.	1.3	65
5	Myelofibrosis in 2019: moving beyond JAK2 inhibition. Blood Cancer Journal, 2019, 9, 74.	6.2	53
6	Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms. Thrombosis, 2011, 2011, 1-8.	1.4	42
7	Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms. Journal of Interferon and Cytokine Research, 2013, 33, 145-153.	1.2	38
8	Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. Experimental Hematology, 2011, 39, 95-101.	0.4	34
9	Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. Annals of Hematology, 2014, 93, 1965-1976.	1.8	34
10	Thrombotic and Bleeding Complications in Classical Myeloproliferative Neoplasms. Seminars in Thrombosis and Hemostasis, 2013, 39, 101-111.	2.7	32
11	Janus kinase inhibitors. Current Opinion in Oncology, 2011, 23, 609-616.	2.4	31
12	Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/Âµl. Blood, 2016, 128, LBA-5-LBA-5.	1.4	29
13	Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. International Journal of Hematology, 2015, 102, 587-593.	1.6	27
14	Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 590-596.	0.4	22
15	From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Blood, 2019, 134, 1902-1911.	1.4	20
16	Critical Roles for Rictor/Sin1 Complexes in Interferon-dependent Gene Transcription and Generation of Antiproliferative Responses. Journal of Biological Chemistry, 2014, 289, 6581-6591.	3.4	19
17	Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 788-795.e2.	0.4	19
18	Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. Leukemia and Lymphoma, 2017, 58, 2786-2798.	1.3	17

#	Article	IF	Citations
19	From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Hematology American Society of Hematology Education Program, 2019, 2019, 397-406.	2.5	17
20	Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Cancer Treatment and Research, 2019, 179, 159-178.	0.5	16
21	Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. International Journal of Hematology, 2017, 105, 44-51.	1.6	15
22	Thrombocytosis and Thrombosis: Is There Really a Correlation?. Current Hematologic Malignancy Reports, 2020, 15, 261-267.	2.3	14
23	Regulatory effects of SKAR in interferon Î± signaling and its role in the generation of type I IFN responses. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11377-11382.	7.1	11
24	Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Postâ€“JAK2V617F Discovery Era. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1238-1245.	4.9	11
25	Long-term antithrombotic therapy after venous stent placement. Phlebology, 2020, 35, 402-408.	1.2	11
26	Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: Prompt resolution of anaphylaxis with the addition of avapritinib. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2534-2536.	3.8	10
27	Evaluation of the Direct Antiglobulin Test (DAT) in the Setting of Mycoplasma pneumoniae Infection. JAMA - Journal of the American Medical Association, 2018, 319, 1377.	7.4	9
28	Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency. Bone, 2020, 141, 115559.	2.9	9
29	Novel therapies for myelofibrosis. Leukemia and Lymphoma, 2015, 56, 2768-2778.	1.3	7
30	Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis. Thrombosis, 2015, 2015, 1-5.	1.4	7
31	Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms. EBioMedicine, 2016, 3, 17-25.	6.1	6
32	Burden of Phlebotomy in Patients with Polycythemia Vera in the United States: Baseline Data from the REVEAL Study. Blood, 2015, 126, 5187-5187.	1.4	5
33	The Need for United Statesâ€“Based Guidelines for Myeloproliferative Neoplasms. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 607-609.	4.9	4
34	Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials. Current Hematologic Malignancy Reports, 2021, 16, 483-489.	2.3	2
35	Disease Characteristics and Prognosis of Myelodysplastic Syndrome Presenting with Isolated Thrombocytopenia. Blood, 2015, 126, 3477-3477.	1.4	2
36	Tissue Factor Bearing Microparticles in the Myeloproliferative Neoplasms. Blood, 2011, 118, 5174-5174.	1.4	2

#	Article	IF	Citations
37	A Phase 1/2, Open-Label, Dose-Escalation, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF). Blood, 2014, 124, 1839-1839.	1.4	2
38	The Natural History Of Polycythemia Vera In Two Diagnostic Eras. Blood, 2013, 122, 4078-4078.	1.4	1
39	Gender Differences In the Prevalence of Thrombosis In the JAK2 V617F-Positive Myeloproliferative Disorders. Blood, 2010, 116, 3080-3080.	1.4	1
40	Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib. Blood, 2014, 124, 1834-1834.	1.4	1
41	Diagnosis and Management of Polycythemia Vera in the Post-JAK2 V617F Discovery Era: A Survey of Practice Patterns. Blood, 2014, 124, 2172-2172.	1.4	1
42	Disease, clinical, and treatment characteristics of patients (pts) with polycythemia vera (PV) enrolled in the REVEAL study.. Journal of Clinical Oncology, 2016, 34, e18557-e18557.	1.6	1
43	Improving Hematology Clinic Access for Patients with Cancer-Associated Thrombosis. Blood, 2021, 138, 1885-1885.	1.4	1
44	Complex hypereosinophilia arising from post-polycythemia vera myelofibrosis: A case of imatinib-responsiveness. Leukemia Research Reports, 2012, 1, 9-12.	0.4	0
45	Cold Agglutinins in Mycoplasma Infectionâ€"Reply. JAMA - Journal of the American Medical Association, 2018, 320, 1039.	7.4	0
46	ASXL1 mutations in idiopathic cytopenias: determined significance?. Leukemia and Lymphoma, 2019, 60, 568-570.	1.3	0
47	Prognosis Is Genetically Fixed In Polycythemia Vera and Definable by Gene Expression Profiling. Blood, 2010, 116, 1987-1987.	1.4	0
48	Could the Increased Prevalence of Thrombotic Complications at High Altitude In Polycythemia Vera (PV) Be Contributed by Hypoxia?. Blood, 2010, 116, 1988-1988.	1.4	0
49	Disruption of the ASXL1 Gene Is Prevalent In PMF: Analysis of Molecular Genetics and Clinical Phenotypes. Blood, 2010, 116, 3074-3074.	1.4	0
50	Age-Related Differences in Disease Characteristics and Clinical Outcomes in Polycythemia Vera. Blood, 2011, 118, 1758-1758.	1.4	0
51	Essential Thrombocytosis: Redefinition in the Genomic Era. Blood, 2014, 124, 3205-3205.	1.4	0
52	Prevalence,Type, and Risk Factors for Bleeding in a Large Cohort of Myeloproliferative Neoplasm Patients. Blood, 2014, 124, 3207-3207.	1.4	0
53	Temporary Vena Cava Filters in Oncology Patients. Blood, 2014, 124, 4247-4247.	1.4	0
54	Permanent inferior vena cava filters in patients with active malignancy.. Journal of Clinical Oncology, 2015, 33, e17655-e17655.	1.6	0

#	Article	IF	Citations
55	Self-Reported Quality-of-Life Impairment and Productivity Loss in Patients with Polycythemia Vera: Early Patient-Reported Outcomes Assessment from the REVEAL Study. Blood, 2015, 126, 4084-4084.	1.4	0
56	Disease and Clinical Characteristics of Patients with Polycythemia Vera: An Early View of the Reveal Study. Blood, 2015, 126, 2813-2813.	1.4	0
57	Self-reported quality-of-life (QoL) impairment and productivity loss in patients with polycythemia vera (PV) enrolled in the REVEAL study.. Journal of Clinical Oncology, 2016, 34, e18561-e18561.	1.6	0
58	Incidence of solid tumors or lymphoma in patients with polycythemia vera: Data from the REVEAL study.. Journal of Clinical Oncology, 2018, 36, e19029-e19029.	1.6	0